Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11657362 | 1.00 | KMT2A (0.52) | KMT2ACA1CA2CA4TRIM24 | |
| Cyclohexane SCHEMBL8879285 | 1.00 | KMT2A (0.52) | KMT2ACA1CA2CA4TRIM24 | |
| Cyclopentane SCHEMBL8879018 | 1.00 | KMT2A (0.52) | KMT2ACA1CA2CA4TRIM24 | |
| SCHEMBL822982 | 1.00 | — | — | |
| SCHEMBL4989703 | 1.00 | KMT2A (0.52) | KMT2ACA1CA2CA4TRIM24 | |
| SCHEMBL28983235 | 1.00 | KMT2A (0.52) | KMT2ACA1CA2CA4TRIM24 | |
| Methane SCHEMBL27674323 | 0.97 | KMT2A (0.50) | KMT2ACA1CA2CA4TRIM24 | |
| SCHEMBL822956 | 0.97 | — | — | |
| Methane SCHEMBL8878704 | 0.95 | — | — | |
| Biphenyl SCHEMBL3157315 | 0.93 | KMT2A (0.46) | KMT2ACA1CA2CA4TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4442241-A2 | RETINOL REPLACEMENT IN SKIN TREATMENT | Symrise AG (DE) | 2024-10-09 | — | — | EP | claimed |
| EP-3773445-B1 | RETINOL REPLACEMENT IN SKIN TREATMENT | SYMRISE AG (DE) | 2024-07-24 | — | — | EP | claimed |
| US-20220331344-A1 | ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS | CHICAGO ATLANTIC ADMIN, LLC | 2022-10-20 | — | — | US | claimed |
| CN-107847772-B | Pharmaceutical composition containing polyalkylene glycol derivative | 西姆莱斯股份公司 | 2022-01-04 | — | — | CN | claimed |
| US-20210212983-A1 | ORAL CANNABINOID DELIVERY FORMULATIONS WITH MOUTHFEEL EXPERIENCE ENHANCERS | CHICAGO ATLANTIC ADMIN, LLC | 2021-07-15 | — | — | US | claimed |
| US-20210045983-A1 | RETINOL REPLACEMENT IN SKIN TREATMENT | SYMRISE AG (DE) | 2021-02-18 | — | — | US | claimed |
| EP-3773445-A1 | RETINOL REPLACEMENT IN SKIN TREATMENT | Symrise AG (DE) | 2021-02-17 | — | — | EP | claimed |
| CN-111918637-A | Retinol substitute in skin treatment | 西姆莱斯有限公司 | 2020-11-10 | — | — | CN | claimed |
| WO-2019185923-A1 | RETINOL REPLACEMENT IN SKIN TREATMENT | SYMRISE AG (DE) | 2019-10-03 | — | — | WO | claimed |
| US-20180185301-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYALKYLENE GLYCOL DERIVATIVES | SYMRISE AG (DE) | 2018-07-05 | — | — | US | claimed |
| WO-2007089652-A2 | FLAVOR-ENHANCING COMPOSITIONS, METHODS OF MANUFACTURE, AND METHODS OF USE | CADBURY ADAMS USA LLC (US) | 2007-08-09 | — | — | WO | claimed |
| US-20070178123-A1 | FLAVOR-ENHANCING COMPOSITIONS, METHOD OF MANUFACTURE, AND METHODS OF USE | KRAFT FOODS GLOBAL BRANDS LLC | 2007-08-02 | — | — | US | claimed |
| WO-2006127738-A9 | COMPRESSIBLE CHEWING GUMS FOR DELIVERY OF ACTIVES | CADBURY ADAMS USA LLC (US) | 2007-05-31 | — | — | WO | claimed |
| US-20060280852-A1 | Vanilla-flavored compositions and delivery systems therefor | CADBURY ADAMS USA LLC. | 2006-12-14 | — | — | US | claimed |
| WO-2006130132-A1 | VANILLA-FLAVORED COMPOSITIONS AND DELIVERY SYSTEMS THEREFOR | CADBURY ADAMS USA LLC (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006127738-A2 | COMPRESSIBLE CHEWING GUMS FOR DELIVERY OF ACTIVES | CADBURY ADAMS USA LLC (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006127602-A2 | CONFECTIONERY COMPOSITION INCLUDING AN ELASTOMERIC COMPONENT AND A COOKED SACCHARIDE COMPONENT | CADBURY ADAMS USA LLC (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006127740-A2 | INDICIA-BEARING PACKAGE FOR DELIVERY SYSTEMS FOR MANAGING RELEASE OF SWEETENERS, SENSATES, FUNCTIONAL INGREDIENTS, FOOD ACIDS AND FLAVORS IN A COMPRESSIBLE GUM SYSTEM | CADBURY ADAMS USA LLC (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006127599-A2 | CONFECTIONERY COMPOSITION INCLUDING AN ELASTOMERIC COMPONENT, A COOKED SACCHARIDE COMPONENT, AND A SENSATE | CADBURY ADAMS USA LLC (US) | 2006-11-30 | — | — | WO | claimed |
| US-20020012640-A1 | Cosmetic composition for stressed skin under extreme conditions | JEFFERIES FINANCE LLC, AS COLLATERAL AGENT | 2002-01-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331344-A1 | ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS | MB, MLEC, NISCH | KMT2A 4605/4885CA1 3845/4885CA2 2859/4885 |
| US-20210045983-A1 | RETINOL REPLACEMENT IN SKIN TREATMENT | RBP1, RBP4, LRAT | KMT2A 3792/4885CA1 4821/4885CA2 4570/4885 |
| US-20180185301-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYALKYLENE GLYCOL DERIVATIVES | PARG, PARN, TRPV1 | KMT2A 3114/4885CA1 2030/4885CA2 557/4885 |
| US-20210212983-A1 | ORAL CANNABINOID DELIVERY FORMULATIONS WITH MOUTHFEEL EXPERIENCE ENHANCERS | CNR2, CNR1, CPNE4 | KMT2A 2218/4885CA1 2883/4885CA2 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.